Results 201 to 210 of about 12,412 (210)

Expert Opinion on Biological Therapy

Expert Opinion on Biological Therapy, 2020
Luca Bianchi, Marina Talamonti, Marco Galluzzo   +2 more
exaly  

Relative efficacy and safety of apremilast, secukinumab, and ustekinumab for the treatment of psoriatic arthritis

Zeitschrift Fur Rheumatologie, 2017
Young Ho Lee, G G Song
exaly  

Efficacy of the anti-IL 17 secukinumab in refractory Behçet's syndrome: A preliminary study

Journal of Autoimmunity, 2019
Giacomo Emmi, Gerardo Di Scala, Alessandra Bettiol   +2 more
exaly  

Severe, ulcerative, lichenoid mucositis associated with secukinumab

JAAD Case Reports, 2016
George Kroumpouzos, Catherine S Yang
exaly  

Secukinumab is Efficacious and Safe in Hispanic Patients with Moderate-to-Severe Plaque Psoriasis: Pooled Analysis of Four Phase 3 Trials

Advances in Therapy, 2017
Luis Puig, César Maldonado-García, Howard Sofen   +2 more
exaly  

Expert Opinion on Drug Safety

Expert Opinion on Drug Safety, 2016

exaly  

Effectiveness and safety of secukinumab in Italian patients with psoriasis: an 84 week, multicenter, retrospective real-world study

Expert Opinion on Biological Therapy, 2019
Serena Lembo, Giuseppe Argenziano, Matteo Megna   +2 more
exaly  

Secukinumab efficacy and safety in Japanese patients with moderate-to-severe plaque psoriasis: Subanalysis from ERASURE, a randomized, placebo-controlled, phase 3 study

Journal of Dermatology, 2014
Mamitaro Ohtsuki, Akimichi Morita, Hidemi Nakagawa   +2 more
exaly  

Activity of secukinumab, an anti-IL-17A antibody, on brain lesions in RRMS: results from a randomized, proof-of-concept study

Journal of Neurology, 2016
Eva Havrdová, Ralph P. Maguire, Hideki Garren   +2 more
exaly  

Efficacy and safety of secukinumab in Taiwanese patients with moderate to severe plaque psoriasis: Subanalysis from ERASURE phase III study

Journal of Dermatology, 2017
Nan-Lin Wu, Fang-Ju Sun
exaly